North Dakota Administrative Code › Title 75 - Department of Human Services › Article 75-09.1 - Substance Abuse Treatment Programs › Chapter 75-09.1-10 - Licensing and Treatment Standards for Opioid Treatment Programs › Section 75-09.1-10-01 - Definitions

Current through Supplement No. 393, July, 2024
In this chapter, unless the context or subject matter
				  otherwise requires:
1. "Accreditation" means the process of review and acceptance
				  by an accreditation body.
2. "Accreditation body" means a body that has been approved
				  by the administration under title 42, Code of Federal Regulations, part 8 to
				  accredit opioid treatment programs using opioid agonist treatment
				  medications.
3. "Administration" means the substance abuse and mental
				  health services administration of the United States department of health and
				  human services.
4. "Certification" means the process by which the
				  administration determines that an opioid treatment program is qualified to
				  provide opioid treatment under federal opioid treatment standards.
5. "Certification application" means the application filed by
				  an opioid treatment program for purposes of obtaining certification from the
				  administration, as described in title 42, Code of Federal Regulations, part
				  8.
6. "Center" means the center for substance abuse treatment
				  within the administration which promotes the quality and availability of
				  community-based substance abuse treatment services to which the administration
				  has delegated certain responsibilities for the certification of opioid
				  treatment programs.
7. "Critical incident" means an event that could have a
				  negative impact on a patient, a patient's family members, or the opioid
				  treatment program or its staff, including an event that involves the loss of
				  life or function, a serious physical or psychological injury, and a medication
				  error.
8. "Detoxification treatment" means the dispensing of an
				  opioid agonist treatment medication in decreasing doses to a patient to
				  alleviate adverse physical or psychological effects incident to withdrawal from
				  the continuous or sustained use of an opioid and to bring the patient to a
				  drug-free state.
9. "Department" means the North Dakota department of human
				  services.
10. "Division" means the division of mental health and
				  substance abuse services of the department.
11. "Division of pharmacologic therapies" means a division of
				  the center, which manages the day-to-day regulatory oversight activities,
				  including supporting the certification and accreditation of opioid treatment
				  programs, necessary to implement title 42, Code of Federal Regulations, part 8,
				  on the use of opioid agonist medications.
12. "Federal opioid treatment standards" means the standards
				  in title 42, Code of Federal Regulations, part 8 that are used to determine
				  whether an opioid treatment program is qualified to engage in opioid treatment
				  and that set forth patient admission criteria.
13. "Health care professional" means a physician assistant or
				  an advanced practice registered nurse working under the medical director's
				  supervision.
14. "Long-term detoxification treatment" means detoxification
				  treatment for longer than thirty days but not in excess of one hundred eighty
				  days.
15. "Maintenance treatment" means the dispensing of an opioid
				  agonist treatment medication at stable dosage levels for a period in excess of
				  thirty days in the treatment of an individual for opioid use disorder.
16. "Medical and rehabilitative services" means services,
				  such as medical evaluations, counseling, and rehabilitative and other social
				  programs such as vocational and educational guidance, and employment placement,
				  intended to help a patient become and remain a productive member of
				  society.
17. "Medical director" means a physician, licensed to
				  practice medicine in the state, who assumes responsibility for administering
				  all medical services performed by the opioid treatment program by whom the
				  medical director is employed, either by performing the services directly or by
				  delegating specific responsibility to authorized opioid treatment program
				  physicians and health care professionals functioning under the medical
				  director's direct supervision.
18. "Medication unit" means a facility established as part
				  of, but geographically separate from, an opioid treatment program from which
				  licensed private medical practitioners or pharmacists dispense or administer an
				  opioid agonist treatment medication or collect biological specimen samples for
				  drug testing or analysis.
19. "Opioid use disorder" reflects compulsive, prolonged
				  self-administration of opioid substances that are used for no legitimate
				  medical purpose or, if another medical condition is present that requires
				  opioid treatment, that are used in doses greatly in excess of the amount needed
				  for that medical condition.
20. "Opioid agonist treatment medication" means any opioid
				  agonist drug that is approved by the United States food and drug administration
				  under section 505 of the Federal Food, Drug, and Cosmetic Act (
				  21 U.S.C.
				  355 ) for use in the treatment of opioid use
				  disorder.
21. "Opioid" means any drug with the natural derivative of
				  opium or synthetic psychoactive substance similar to morphine with capability
				  to create physical dependence.
22. "Opioid treatment" means the dispensing of an opioid
				  agonist treatment medication, and the provision of a comprehensive range of
				  medical and rehabilitative services, when clinically necessary, to an
				  individual to alleviate the adverse medical, psychological or physical effects
				  of an opioid use disorder.
23. "Opioid treatment program" means a program engaged in
				  opioid treatment, which is:
a. Certified as an opioid treatment program by the
				  center;
b. Registered by the United States department of justice,
				  drug enforcement administration under 21 U.S.C. section 823(g);
c. Accredited by an opioid treatment program accreditation
				  body; and
d. Licensed as an opioid treatment program by the
				  division.
24. "Patient" means an individual who undergoes treatment in
				  an opioid treatment program.
25. "Program sponsor" means the person named in the
				  application for certification under title 42, Code of Federal Regulations, part
				  8 as responsible for the operation of the opioid treatment program.
26. "Short-term detoxification treatment" means
				  detoxification treatment for a period not in excess of thirty days.
27. "Treatment plan" means a plan that outlines for each
				  patient attainable short-term treatment goals that are mutually acceptable to
				  the patient and the opioid treatment program and which specifies the services
				  to be provided and the frequency and schedule for their
				  provision.
General Authority:
NDCC
					 50-31-08
Law Implemented:
NDCC
					 50-31-08